Pennsylvania | Belgium
| Investor Type | Firm |
| Industries | BioTech • A.I. (& Big Data) • HealthTech (& Fitness) • Impact • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Consumer • Pharmaceutical (& Medicine) |
| Stages | Seed, Series A, Series B |
| Investing | United States • Belgium |
| Investment Range | $100,000 - $5,000,000 |
| Investment Sweet Spot | $1,500,000 |
| Assets Under Management | $47,700,000 |
About The Fund
New Rhein Healthcare Investors is an investment fund that specializes in sectors of BioTech, A.I. (& Big Data), HealthTech (& Fitness), Impact, Medical Devices (& Hospital Services), Healthcare (& Wellness), Consumer, and Pharmaceutical (& Medicine). Their investment strategy is built around a minimum investment of $100,000 and a maximum of $5,000,000, with a 'sweet spot' for investments typically around $1,500,000. The fund has a particular focus on Seed, Series A, and Series B financing rounds, seeking opportunities to drive innovation and steer growth within their areas of expertise. They have assets under management totaling $47,700,000, indicative of their significant stake in the healthcare and life sciences sectors. New Rhein's website also highlights their operational aspects, such as utilizing information to operate, manage, develop, and promote their business, ensuring compliance with legal and regulatory obligations, and implementing reviews for business-protection purposes. They partake in protecting their operations from various financial and business crimes, and they may conduct reviews to disclose information relevant to litigation or investigations. The team includes executives with extensive experience in the pharmaceutical industry, such as Dr. Ivan Gergel, the Chief Medical Officer & Managing Partner at New Rhein, with a history of drug approvals and leadership in pharmaceutical R&D. New Rhein's portfolio contains a variety of companies in healthcare-related fields, including Corsair, American Injectables, Theranica, Sayvaa Pharma, Neuraptive, Softhale, Butterfly Medical, Biocartis, Chase, and Novagali, representing their investment interests and diverse approach within the fund's specializations.
Contact over 100,000 investors!
Built by serial entrepreneurs and ex-VCs, Angels Partners helps entrepreneurs connect with relevant investors in their industry.
With over 100K+ listed investors, our mission is to help founders secure meetings & accelerate their fundraising.
View previous deals, filter by deal size, industry, location and more. It's the fastest way to build a target investor list.
e
We also built a community of hundreds of investors actively prospecting & investing directly on Angels Partners.
Register to become visible to a large community of investors on our platform.
- Prime Founders
- 85 Great Portland St.
- London, U.K.
- contact@angelspartners.com
